Claims for Patent: 8,221,795

Summary for Patent: 8,221,795

Title:	Composition of imaging nanoparticles
Abstract:	The invention relates to a method of managing a tumor of an animal subject comprising imaging the tumor by delivering a dosage of imaging nanoparticles to the tumor site, the imaging nanoparticles consisting of positively charged chitosan, optionally a zero-charge substance or bioactive agent, and a negatively charged substrate having gadolinium (Gd) chelated to the negatively charged substrate.
Inventor(s):	Sung; Hsing-Wen (Hsinchu, TW), Sonaje; Kiran (Hsinchu, TW), Nguyen; Ho-Ngoc (Hsinchu, TW), Chuang; Er-Yuan (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA)
Assignee:	GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW)
Application Number:	13/374,046
Patent Claims:	1. A method of managing a tumor of an animal subject comprising imaging said tumor by delivering a dosage of imaging nanoparticles to the tumor site, the imaging nanoparticles consisting of positively charged chitosan, optionally a ligand or bioactive agent, and a negatively charged substrate having gadolinium (Gd) chelated to the negatively charged substrate. 2. The method of claim 1, wherein said chitosan is N-trimethyl chitosan, EDTA-chitosan, low molecular weight chitosan, PEG-chitosan, mono-N-carboxymethyl chitosan, chitosan derivatives, or combinations thereof. 3. The method of claim 2, wherein said ligand is attached to a free --NH.sub.3 group of the N-trimethyl chitosan. 4. The method of claim 1, wherein the ligand is galactosamine. 5. The method of claim 1, wherein the ligand includes a substrate, inhibitor, activator, or neurotransmitter. 6. The method of claim 1, wherein said negatively charged substrate is a PGA-complexone conjugate, .gamma.-PGA, .alpha.-PGA, derivatives of PGA, salts of PGA, or combinations thereof. 7. The method of claim 6, wherein the PGA-complexone conjugate is PGA-DTPA or PGA-EGTA. 8. The method of claim 1, wherein said nanoparticles are delivered via an oral route or via a parenteral route. 9. The method of claim 1, wherein the imaging is for brain tumor enhancement associated with degradation of a blood-brain barrier. 10. The method of claim 1, wherein said nanoparticles are encapsulated in a capsule. 11. The method of claim 10, wherein said capsule further comprises a pharmaceutically acceptable carrier, diluent, excipient, or absorption enhancer. 12. The method of claim 10, wherein said capsule further comprises at least a solubilizer, bubbling agent, or emulsifier. 13. The method of claim 10, wherein said capsule is treated with an enteric coating polymer. 14. The method of claim 1, wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form. 15. The method of claim 14, wherein said freeze-dried nanoparticles are being re-constituted with sterile water prior to being delivered to the animal subject. 16. The method of claim 1, wherein the nanoparticles are used in enhancing imaging contrast quality or property during an imaging procedure. 17. The method of claim 1, wherein the bioactive agent is an anti-cancer drug. 18. The method of claim 1, wherein the nanoparticles are treated with an enteric coating polymer. 19. The method of claim 1, wherein the method further comprises a step of targeting said tumor by enclosing a tumor targeting moiety within the nanoparticles. 20. The method of claim 1, wherein the bioactive agent is selected from the group consisting of nystatin, antifungal agent, itraconazole, fluconazole, mesalazine, prednisone, a TNF inhibitor, azathioprine (Imuran), methotrexate, or 6-mercaptopurine.

Details for Patent 8,221,795

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2025-01-04